Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.815
+0.024 (3.07%)
At close: Dec 24, 2024, 4:00 PM
0.792
-0.023 (-2.82%)
After-hours: Dec 24, 2024, 4:47 PM EST
Imunon Employees
Imunon had 33 employees as of December 31, 2023. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$589,429
Market Cap
11.82M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Marinus Pharmaceuticals | 166 |
Cosmos Health | 123 |
STRATA Skin Sciences | 99 |
Lyra Therapeutics | 88 |
Turnstone Biologics | 80 |
Ekso Bionics Holdings | 72 |
Sol-Gel Technologies | 36 |
AIM ImmunoTech | 28 |
IMNN News
- 6 days ago - IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewsWire
- 15 days ago - IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - GlobeNewsWire
- 4 weeks ago - IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer - GlobeNewsWire
- 6 weeks ago - Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire
- 6 weeks ago - IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - GlobeNewsWire
- 2 months ago - IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire